!– Request: news/blog/author/qiagenb –> <!– Matched Rewrite Rule: news/blog/author/([^/]+)/?$ –> <!– Matched Rewrite Query: author_name=qiagenb –> <!– Loaded Template: index.php –>
For clinical diagnostic labs, changing to a new informatics platform is not an easy decision. However, if your lab is currently using Illumina’s TruSight Oncology 500 (TSO500) assay, now may be the perfect time to switch to QCI Interpret for Oncology—QIAGEN’s clinical informatics platform for variant analysis, interpretation, and reporting.
Recent acquisitions within the biotech industry are leaving certain labs with questions about continuing with their current informatics platform. That’s why we want to spotlight a major opportunity for TSO500 users who are using Illumina’s non-exclusive partner for variant interpretation and reporting.
In this article, we explore the benefits of switching to QCI Interpret for Oncology, provide a head-to-head comparison of QIAGEN and a key competitor, and give you the opportunity to request a complementary, custom report for your TSO500 workflow.
QCI Interpret for Oncology is a clinical informatics platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale.
Connected to the exclusive QIAGEN Knowledge Base, the industry’s most comprehensive, manually curated resource that is updated weekly, QCI Interpret for Oncology dynamically computes pathogenicity and actionability based on the AMP/ASCO/CAP or ACMG/AMP guidelines for every variant in over 31,000 cancer types with full transparency. To simplify and accelerate interpretation, users have access to over 410,000 preformulated, oncologist-reviewed variant impact summaries to build custom, patient-specific reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials.
|QIAGEN Knowledge Base||Competitor P*|
|NGS test interpretations||3 million+||100,000+|
|Curated somatic genes||2,600+||1,250+|
|Curated somatic variants||6.4 million+||Unknown|
|Oncologist-reviewed interpretative comments||419,000+||0|
|Years of curation||25||9|
QCI Interpret for Oncology offers clinical diagnostic labs a multitude of unique features not available in most competitor solutions.
|QCI Interpret||Competitor P*|
|Offers secondary analysis solution||Yes||No|
|Offers variant curation and interpretation services||Yes||No|
|Supports somatic and germline workflows||Yes||No|
|Oncologist-reviewed interpretative comments||Yes||No|
|Global informatics support||Yes||No|
In a 2022 study evaluating the performance and clinical utility of optical genome mapping and the TruSight Oncology 500 panel for comprehensive genomic profiling of 15 myeloid tumors, QCI Interpret for Oncology was used for the variant analysis and interpretation. The researchers found that QCI Interpret for Oncology was 100% concordant in classifying the variants into correct tier-based classifications as compared to expertly classified reported variants.